Product Overview

AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.

HematoOncology

BESREMi®

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

Drug Facts
Active Ingredient
Ropeginterferon alfa-2b
HematoOncology

Busilvex®

Busilvex® is a concentrate used to conditioning treatment prior to stem cell transplantation. Pierre Fabre is the MA-Holder and AOP Orphan has the distribution right.

Drug Facts
Active Ingredient
Busulfan
Neurology & Metabolic Disorders

Feraccru®

Feraccru® is indicated for adults for the treatment of iron deficiency.

Drug Facts
Active Ingredient
Ferric-maltol
Neurology & Metabolic Disorders

Motetis®

Motetis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in etiologist such as tardive dyskinesia, tics and dystonia.

Drug Facts
Active Ingredient
Tetrabenazine
Neurology & Metabolic Disorders

Ocaliva®

Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

Drug Facts
Active Ingredient
Obeticholic acid
Cardiology & Pulmonology

TRESUVI®

Drug Facts
Active Ingredient
Treprostinil
HematoOncology

Thromboreductin®

Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients

Drug Facts
Active Ingredient
Anagrelide
Neurology & Metabolic Disorders

Wakix®

Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.

Drug Facts
Active Ingredient
Pitolisant